Tenaya Therapeutics (TNYA) Other Non-Current Liabilities (2020 - 2026)
Tenaya Therapeutics (TNYA) recorded quarterly Other Non-Current Liabilities of $418000.0 in Q1 2026, up 1.95% quarter-over-quarter from $410000.0 in Q4 2025, and up 45.64% on a YoY basis from $287000.0 in Q1 2025.
Tenaya Therapeutics (TNYA) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Tenaya Therapeutics' Other Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $418000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 45.64% year-over-year to $418000.0; the TTM figure through Mar 2026 stood at $418000.0 (up 45.64% YoY), while the FY2025 annual figure was $410000.0, up 45.91% from the prior year.
- Other Non-Current Liabilities was $418000.0 for Q1 2026 at Tenaya Therapeutics, up from $410000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $418000.0 in Q1 2026 to a low of $212000.0 in Q1 2022.
- Historically, Other Non-Current Liabilities has averaged $273176.5 across 5 years, with a median of $259000.0 in 2024.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities jumped 7133.33% in 2022, then climbed 9.06% in 2025.
- A 5-year view of Other Non-Current Liabilities shows it stood at $228000.0 in 2022, then increased by 10.96% to $253000.0 in 2023, then climbed by 11.07% to $281000.0 in 2024, then soared by 45.91% to $410000.0 in 2025, then increased by 1.95% to $418000.0 in 2026.
- The last three Other Non-Current Liabilities figures came in at $418000.0 (Q1 2026), $410000.0 (Q4 2025), and $301000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Tenaya Therapeutics | 158.32 Mn | 158.32 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 418,000.00 |
| Dec 31, 2025 | 410,000.00 |
| Sep 30, 2025 | 301,000.00 |
| Jun 30, 2025 | 293,000.00 |
| Mar 31, 2025 | 287,000.00 |
| Dec 31, 2024 | 281,000.00 |
| Sep 30, 2024 | 276,000.00 |
| Jun 30, 2024 | 266,000.00 |
| Mar 31, 2024 | 259,000.00 |
| Dec 31, 2023 | 253,000.00 |
| Sep 30, 2023 | 246,000.00 |
| Jun 30, 2023 | 240,000.00 |
| Mar 31, 2023 | 234,000.00 |
| Dec 31, 2022 | 228,000.00 |
| Sep 30, 2022 | 223,000.00 |
| Jun 30, 2022 | 217,000.00 |
| Mar 31, 2022 | 212,000.00 |
| Dec 31, 2021 | 182,000.00 |
| Sep 30, 2021 | 96,000.00 |
| Jun 30, 2021 | 3,000.00 |